Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

Abstract: Single-domain shark variable new antigen receptor (VNAR) monoclonal antibodies that specifically bind programmed death-ligand 1 (PD-L1) are described. The PD-L1-specific VNAR antibodies are capable of binding PD-L1-expressing tumor cells from human, mouse and canine origin. Immune cells expressing chimeric antigen receptors (CARs) developed using the VNAR antibodies can be used to kill PD-L1-positive tumor cells, for example in animal models of liver cancer and breast cancer.

Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: Single-domain monoclonal antibodies that specifically bind Lassa virus glycoprotein (GPC) are described. The single-domain antibodies (“nanobodies”) were isolated from camel (VHH) and shark variable new antigen (VNAR) phage display libraries panned against a stabilized form of the GPC trimer. The GPC-specific nanobodies, and conjugates thereof, can be used for the diagnosis and treatment of a Lassa virus infection.

Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

Abstract: Polypeptides that specifically bind the spike (S) protein of human coronavirus, selected from six camel VHH single domain antibody phage display libraries, are described. The S protein-specific polypeptides disrupt binding of the SARS-CoV-2 and/or SARS-CoV S protein to the cellular receptor ACE2, which is important for neutralization of the virus. Use of the S protein-specific polypeptides for the diagnosis and treatment of SARS-CoV-2 and/or SARS-CoV is described.

Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

Abstract: Optimized chimeric antigen receptors (CARs) targeting glypican-1 (GPC1) that include a 12-amino acid hinge region from IgG4 are described. The optimized CARs include a transmembrane domain from either CD8 or CD28. Immune cells, such as T cells or natural killer cells, expressing the optimized CARs can be used to treat GPC1-positive solid tumors.

Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: The invention refers to a method performed by a performance recommender for a wireless network, obtaining (2010) for a plurality of cells input data, the input data comprising actual cell configuration parameter values; applying (2030) a machine-learning model to the input data to generate, for at least a portion of the cells, one or more recommendations for changes to the cell configuration parameter values to improve uplink, UL, performance in the respective cells; and based on identifying conflicts between recommendations for different cells, partitioning (2040) the plurality of cells into a plurality of interaction areas of neighboring cells; resolving (2050) conflicts in recommendations for respective cells within each of the interaction areas and across different interaction areas; and for at least a portion of the cells, determining (2060) preferred values for the cell configuration parameters to improve UL performance in the respective cells; the invention further relates to a corresponding performanc

Abstract: Single-domain monoclonal antibodies that specifically bind B7H3 (also known as CD276) are described. The single-domain antibodies include camel VHH and rabbit VH domain nanobodies selected from phage display libraries. Chimeric antigen receptors (CARs) and other antibody conjugates targeted to B7H3 are also described. The single-domain antibodies and conjugates thereof can be used for the diagnosis and treatment of B7H3 expressing solid tumors.

Abstract: A method is provided for identifying operating conditions of a system. Input data relating to operation of the system is applied to a multi-class model for classification, where the multi-class model is configured for classifying the data into one of a plurality of predefined classes, and each class corresponds to a respective operating condition of the system. A confidence level of the classification by the multi-class model is determined. If the confidence level is below a threshold confidence level, the input data is applied to a plurality of binary models, where each binary model is configured for determining whether the data is or is not in a respective one of the predefined classes. If the plurality of binary models determine that the data is not in any of the respective predefined classes, the data can be taken into consideration when updating the multi-class model.

Abstract: The present invention refers to a method and apparatus and computer program for detecting communities in a radio access network with a plurality of vertices (C, BBU), wherein the method comprises calculating (S11) relationship strengths (31, 41) for network connections between the vertices (C, BBU) by executing a connection strength calculation process by analyzing performance factors, decisive for network performance including cell coverage overlap, signal strength, and inter-cell interference. The method further creates (S12) a network graph with nodes, representing the vertices (C,BBU) in the network and edges, representing the network connections based on the calculated relationship strengths (31, 41) and applies (S13) an extended iterative disjoint community detection algorithm for clustering nodes into communities, wherein in each iteration imposed one or more constraints for clustering cooperating nodes into the same community are analyzed (S14).

Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of reducing the activity of TNF? converting enzyme, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.

Abstract: A method 300 is disclosed for generating and training a model to detect interference conditions at a cell in a wireless cellular network and to classify the impact of detected interference conditions on performance of the wireless cellular network in the cell. The method comprises, for each of a plurality of cells in the wireless cellular network (360), obtaining data representing received signal power at a base station serving the cell over a period of time (310) and obtaining data representing a plurality of performance metrics for the cell over the time period (330). The method further comprises obtaining classifications of the received signal power data into one of a plurality of cell interference conditions (320) and the performance metric data into one of a plurality of cell impact classes (340).

Abstract: Monoclonal antibodies that specifically bind glypican-1 (GPC1) are described. Chimeric antigen receptor (CAR) T cells, immunotoxins and other antibody conjugates based on the GPC1-specific antibodies are also described. The disclosed CAR T cells, immunotoxins, GPC1-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of GPC1-positive pancreatic cancer and other cancers.

Abstract: Camel single-domain monoclonal antibodies that specifically bind human and mouse mesothelin are described. Chimeric antigen receptor (CAR) T cells and antibody conjugates based on the mesothelin-specific antibodies are also described. The disclosed CAR T cells, mesothelin-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of mesothelin-positive cancers.

Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.